- Open Access
Dissecting the roles of thymoquinone on the prevention and the treatment of hepatocellular carcinoma: an overview on the current state of knowledge
- Sabrina Bimonte†1Email authorView ORCID ID profile,
- Vittorio Albino†2,
- Antonio Barbieri†3,
- Maria Luisa Tamma1,
- Aurelio Nasto4,
- Raffaele Palaia2,
- Carlo Molino5,
- Paolo Bianco6,
- Andrea Vitale6,
- Rita Schiano6,
- Aldo Giudice7 and
- Marco Cascella†1
© The Author(s). 2019
- Received: 7 December 2018
- Accepted: 8 April 2019
- Published: 16 April 2019
Thymoquinone (TQ) is the principal active monomer isolated from the seed of the medicinal plant Nigella sativa. This compound has antitumor effects against various types of cancer including hepatocellular carcinoma (HCC), mainly due to its anti-inflammatory and anti-oxidant properties. Several pre-clinical studies showed that TQ, through the modulation of different molecular pathways, is able to induce anti-apoptotic and anti-proliferative effects in HCC, without signs of toxicity. Moreover, it has been suggested that TQ has hepatoprotective effects by enhancing the tolerability and effectivity of neoadjuvant therapy prior to liver surgery, although the underlying mechanisms are not completely understood. Based on these findings, is assumable that TQ could represent a valuable therapeutic option for patients suffering from HCC. In this review, we summarize the potential roles of TQ in the prevention and treatment of HCC, by revising the preclinical studies and by highlighting the potential applications of TQ as a therapeutic choice for HCC treatment into clinical practices.
- Nigella sativa
- Hepatocellular carcinoma
- Cell proliferation
- Cell apoptosis
Thymoquinone (TQ) is the predominant bioactive constituent present in the volatile oil of black seed (Nigella sativa), particularly used as a condiment in the Middle East [1–4]. Accumulating of evidence showed that TQ has anti-oxidant effects and anti-proliferative effects in many types of cancer, including liver tumors, without signs of toxicity to normal cells [5–11]. Moreover, it has been proved that TQ and Nigella sativa possess hepatoprotective effects by enhancing the tolerability and the effectivity of neoadjuvant therapy prior to liver surgery [12–16]. As regards to hepatocellular carcinoma (HCC), due to the unavailability of successful therapy for HCC patients mainly for those at an advanced stage of disease [17–20], new alternative therapies based on the use of natural compounds as a supplement to conventional schedules for HCC treatment, should be taken into account . Based on these findings, is assumable that TQ could be considered a therapeutic option for the prevention and the treatment of HCC. For this purpose, we summarize the potential roles of TQ in the prevention and treatment of HCC, by revising the preclinical studies and by highlighting the potential applications of TQ as a therapeutic choice for HCC treatment into clinical practices.
TQ: chemical structure, biological properties, and roles in the human hepatocellular carcinoma
Pre-clinical shreds of evidence on the role of TQ in HCC cell growth: a current state of the art
A summary of pre-clinical studies on the role of TQ in hepatocellular carcinoma cell growth
Dose of TQ
Rats with Hepatocarcinogenesis-induced by diethylnitrosamine (DENA 200 mg/kg, I.P.).
50 mg/L in drinking water = 4 mg/kg daily for 7 consecutive days.
GSHPx↑, CAT↑ GST↑
Rats with hepatocarcinogenesis induced by N-nistrodiethhylamine (NDEA, 0,01% in drinking water)
20 mg/kg body weight daily from the 3th to 5th week of treatments.
Ki67↓, PCNA, Cyclin D1↓, CDK4↓ and p21WAF1/CIP1↑,
12.5, 25 or 50 M μM for 24 h.
NF-κB↓, IL-8 ↓, ROS↑ NQO1↑ HO-1↑, Bcl-xS↑, TRAIL death receptors↑; Bcl-2↓
Hep3B, SMMC7721, HepG2, Bel7402, MHCC97-L, MHCC97-H, HHCC
20,40,60, 80 μM from 24 to 72 h.
Bcl-2↓, Notch1↓, NICD1↓, Jagged1↓, Hes1↓ cyclin D1↓, CDK2↓ p21↑, Bax↑
Liver tumor xenografts in athymic nude mice (Hep cells)
5 mg/kg daily (subcutaneously injected); 20 mg/kg daily (subcutaneously injected) for 31 days.
NICD1↓, Bcl-2↓, Notch1↓, p21↑
Similar findings were reported by Ashour et al in vitro experiments on HepG2 cells . Specifically, TQ was able to inhibit the growth of HCC cells by arresting cell cycle on G2M phase and by activating the expression of caspase-3 and caspase-9 and the cleavage of poly (ADP-ribose) polymerase. Moreover, TQ was able to enhance the TRAIL-induced death of HepG2 cells, thought the up-regulation of death receptors, the inhibition of Nuclear factor kappa-B (NF-κB) and interleukin-8 (IL-8), the stimulation of reactive oxygen species (ROS) and mRNAs of NAD(P)H quinone dehydrogenase 1 (NQO1) and heme oxygenase 1 (HO-1). These results suggest that TQ could be considered a potential substance for the prevention and the treatment of HCC. In a fascinating in vitro and in vivo studies, a pivotal role of TQ in the inhibition of HCC cell growth was also reported . Basically, the authors showed a retarded tumor cell growth induced by TQ treatment accompanied by arresting the cell cycle in G1 phase (SMMC7721 cells) or in S phase (Hep3B cells) and by upregulating p21 and downregulating CDK2 and cyclinD1 expression according to TQ concentrations. Moreover, TQ enhanced apoptosis by decreasing Bcl-2 expression and increasing Bax expression. These findings were confirmed in a xenograft mouse model of HCC. Particularly, tumors of xenograft liver mice showed a decreased expression of NICD1 and Bcl-2 levels while an increment of p21 expression was observed. Altogether, these data suggest that TQ inhibits HCC growth by inhibiting the Notch signaling pathway.
Mechanism of action: a link between the hepatoprotective effects of TQ and its antioxidant properties
Despite the inhibitory role of TQ on HCC cell growth, several in vivo reports on different liver models [13, 35–53], shed a light on the hepatoprotective effects of TQ, commonly associated to its antioxidant properties. In a fascinating systematic review, Tekbas et al.  suggested that TQ, due to its multiple properties, could be considered as a new substance that reduced the hepatic injury.
It is well assumed, that liver injury is commonly associated with changes in the expression of the principal liver enzymes and in liver tissue damage which is commonly attributed to an oxidative stress . Results from the above-mentioned studies on different liver models suggest that TQ has a hepatoprotective role by increasing the resistance to oxidative stress, through the regulation of the oxidative markers content.
Specifically, TQ is able to prevent malondialdehyde (MDA) production [37–45], to block the lipid peroxidation [38, 46–49], to reduce the content of nitric oxide (NO) [50, 52] and to decrease the concentration of GSH [39, 43, 44, 49–51, 53]. The underlying mechanism is mainly based on the inhibition of oxygen free radicals production induced by TQ, which in turn regulates the inflammatory molecular pathways as NF-kB, tumor necrosis factor (TNF-α), interleukin (IL-1β) and the nitric oxide signaling pathway.
An interesting study on the protective mechanism of TQ on HCC was recently demonstrated in rats with HCC induced by diethylnitrosamine (DENA) . The authors identified the EGFR/ERK1/2 signaling pathway as the underlying mechanism by which TQ exerted the hepatoprotective function. Moreover, TQ was able to protect liver thanks to its antioxidant properties by enhancing the activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and glutathione- s-transferase (GST).
Taken together, these findings, suggest that TQ could be considered not only a potential drug for the prevention and the treatment of HCC but also as a hepatoprotective agent in HCC patients.
Several pre-clinical studies depicted here demonstrated that TQ induces apoptosis and restrains HCC progression by acting on different molecular pathways. These findings largely support the use of TQ into clinical practice for HCC counteraction and treatment. Despite TQ compound is currently used in clinical trials for the treatment of different type of cancer and other diseases, no clinical trials have been performed, until now, for patients suffering from HCC. For these reasons, more studies are extremely needed. These examinations ought to be engaged 1) on the understanding of the molecular mechanism regulated by TQ in HCC; 2) on the identification of the optimum therapeutic dosage of TQ for intervention trials in HCC patients.
The authors are grateful to Alessandra Trocino and Mrs. Maria Cristina Romano from the National Cancer Institute of Naples for providing excellent bibliographic service and assistance.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
The present review was mainly written by SB and MC. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here to eternity-the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther. 2008;6:495–510.PubMedPubMed CentralGoogle Scholar
- Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17:299–305.View ArticleGoogle Scholar
- Cascella M, Bimonte S, Barbieri A, et al. Dissecting the potential roles of Nigella sativa and its constituent Thymoquinone on the prevention and on the progression of Alzheimer's disease. Front Aging Neurosci. 2018;10:16.View ArticleGoogle Scholar
- Cascella M, Palma G, Barbieri A, et al. Role of Nigella sativa and its constituent Thymoquinone on chemotherapy-induced nephrotoxicity: evidences from experimental animal studies. Nutrients. 2017;9(6):625.View ArticleGoogle Scholar
- Woo CC, Hsu A, Kumar AP, Sethi G, Tan KH. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p3 MAPK and ROS. PLoS One. 2013;8:e75356.View ArticleGoogle Scholar
- Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1-targeted Thymoquinone therapy for hormone-refractory prostate Cancer. Cancer Res. 2007;67:7782–8.View ArticleGoogle Scholar
- Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009;69:5575–83.View ArticleGoogle Scholar
- Li F, Rajendran P, Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol. 2010;161:541–54.View ArticleGoogle Scholar
- Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443–51.View ArticleGoogle Scholar
- Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 2010;29(1):87.View ArticleGoogle Scholar
- Ashour AE, Abd-Allah AR, Korashy HM, Attia SM, Alzahrani AZ, Saquib Q, Bakheet SA, Abdel-Hamied HE, Jamal S, Rishi AK. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol Cell Biochem. 2014;389:85–98.View ArticleGoogle Scholar
- Tabassum H, Ahmad A, Ahmad IZ. Nigella sativa L. and its bioactive constituents as Hepatoprotectant: a review. Curr Pharm Biotechnol. 2018;19:43.View ArticleGoogle Scholar
- Tekbas A, Huebner J, Settmacher U, Dahmen U. Plants and surgery: the protective effects of Thymoquinone on hepatic injury-a systematic review of in vivo studies. Int J Mol Sci. 2018;19(4):1085.View ArticleGoogle Scholar
- Mollazadeh H, Afshari AR, Hosseinzadeh H. Review on the potential therapeutic roles of Nigella sativa in the treatment of patients with Cancer: involvement of apoptosis: - Black cumin and cancer. J Pharmacopuncture. 2017;20(3):158–72.View ArticleGoogle Scholar
- Shahin YR, Elguindy NM, Abdel Bary A, Balbaa M. The protective mechanism of Nigella sativa against diethylnitrosamine-induced hepatocellular carcinoma through its antioxidant effect and EGFR/ERK1/2 signaling. Environ Toxicol. 2018;33:885–98.View ArticleGoogle Scholar
- Abd-Elbaset M, Arafa ESA, El Sherbiny GA, Elgendy AN. Thymoquinone mitigate ischemia-reperfusion-induced liver injury in rats: a pivotal role of nitric oxide signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2017;390:69.View ArticleGoogle Scholar
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.View ArticleGoogle Scholar
- Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–32.View ArticleGoogle Scholar
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.View ArticleGoogle Scholar
- Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of Sorafenib plus Erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–66.View ArticleGoogle Scholar
- Moreno FS, Heidor R, Pogribny IP. Nutritional epigenetics and the prevention of hepatocellular carcinoma with bioactive food constituents. Nutr Cancer. 2016 Jul;68(5):719–33.View ArticleGoogle Scholar
- Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 2003;22:107–13.PubMedGoogle Scholar
- Relles D, Chipitsyna GI, Gong Q, Yeo CJ, Arafat HA. Thymoquinone promotes pancreatic Cancer cell death and reduction of tumor size through combined inhibition of histone Deacetylation and induction of histone acetylation. Adv Prev Med. 2016;2016:1407840.View ArticleGoogle Scholar
- Samarghandian S, Azimi-Nezhad M, Farkhondeh T. Thymoquinone-induced antitumor and apoptosis in human lung adenocarcinoma cells. J Cell Physiol. 2018:1–11.Google Scholar
- Badary OA, Gamal El-Din AM. Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcomatumorigenesis. Cancer Detect Prev. 2001;25(4):362–8.PubMedGoogle Scholar
- Arumugam P, Subramanian R, Priyadharsini JV, Gopalswamy J. Thymoquinone inhibits the migration of mouse neuroblastoma (Neuro-2a) cells by down-regulating MMP-2 and MMP-9. Chin J Nat Med. 2016;14(12):904–12.PubMedGoogle Scholar
- Peng L, Liu A, Shen Y, Xu H, Yang S, Ying X, Shen W. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol Rep. 2013;29:571–8.View ArticleGoogle Scholar
- Siveen KS, Mustafa N, Li F, et al. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget. 2013;5(3):634–48.PubMed CentralGoogle Scholar
- Badary OA, Taha RA, Gamal El-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol. 2003;26(2):87–98.View ArticleGoogle Scholar
- Khan MA, Younus H. Thymoquinone shows the diverse therapeutic actions by modulating multiple cell signaling pathways: single drug for multiple targets. Curr Pharm Biotechnol. 2018;19(12):934–45.View ArticleGoogle Scholar
- Ke X, Zhao Y, Lu X, et al. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of notch signaling. Oncotarget. 2015;6(32):32610–21.View ArticleGoogle Scholar
- Sayed-Ahmed MM, Aleisa AM, Al-Rejaie SS, et al. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxidative Med Cell Longev. 2010;3(4):254–61.View ArticleGoogle Scholar
- Raghunandhakumar S, Paramasivam A, Senthilraja S, Naveenkumar C, Asokkumar S, Binuclara J, Jagan S, Anandakumar P, Devaki T. Thymoquinone inhibits cell proliferation through regulation of G1/S phase cell cycle transition in N-nitrosodiethylamine-induced experimental rat hepatocellular carcinoma. Toxicol Lett. 2013;223(1):60–72.View ArticleGoogle Scholar
- Ashour AE, Abd-Allah AR, Korashy HM, Attia SM, Alzahrani AZ, Saquib Q, Bakheet SA, Abdel-Hamied HE, Jamal S, Rishi AK. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol Cell Biochem. 2014;389(1–2):85–98.View ArticleGoogle Scholar
- Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, Al-Sawaf HA. Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol. 2001;110:239–51.PubMedGoogle Scholar
- Mansour MA. Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci. 2000;66:2583–91. https://doi.org/10.1016/S0024-3205(00)00592-39.View ArticlePubMedGoogle Scholar
- Nili-Ahmadabadi A, Tavakoli F, Hasanzadeh G, Rahimi H, Sabzevari O. Protective effect of pretreatment with thymoquinone against Aflatoxin B(1) induced liver toxicity in mice. Daru. 2011;19:282–7.PubMedPubMed CentralGoogle Scholar
- Al-Malki AL, Sayed AA. Thymoquinone attenuates cisplatin-induced hepatotoxicity via nuclear factor kappa-beta. BMC Complement Altern Med. 2014;14:282.View ArticleGoogle Scholar
- Aycan IO, Tufek A, Tokgoz O, Evliyaoglu O, Firat U, Kavak GO, Turgut H, Yuksel MU. Thymoquinone treatment against acetaminophen-induced hepatotoxicity in rats. Int J Surg. 2014;12:213–8.View ArticleGoogle Scholar
- El-Sheikh AA, Morsy MA, Abdalla AM, Hamouda AH, Alhaider IA. Mechanisms of Thymoquinone Hepatorenal protection in methotrexate-induced toxicity in rats. Mediat Inflamm. 2015;2015:859383.View ArticleGoogle Scholar
- Farag MM, Ahmed GO, Shehata RR, Kazem AH. Thymoquinone improves the kidney and liver changes induced by chronic cyclosporine a treatment and acute renal ischaemia/reperfusion in rats. J Pharm Pharmacol. 2015;67:731–9.View ArticleGoogle Scholar
- Helal GK. Thymoquinone supplementation ameliorates acute endotoxemia-induced liver dysfunction in rats. Pak J Pharm Sci. 2010;23:131–7.PubMedGoogle Scholar
- Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:381–91.View ArticleGoogle Scholar
- Attia A, Ragheb A, Sylwestrowicz T, Shoker A. Attenuation of high cholesterol-induced oxidative stress in rabbit liver by thymoquinone. Eur J Gastroenterol Hepatol. 2010;22:826–34.View ArticleGoogle Scholar
- Mohany M, El-Feki M, Refaat I, Garraud O, Badr G. Thymoquinone ameliorates the immunological and histological changes induced by exposure to imidacloprid insecticide. J Toxicol Sci. 2012;37:1–11. https://doi.org/10.2131/jts.37.1.View ArticlePubMedGoogle Scholar
- Nagi MN, Alam K, Badary OA, Al-Shabanah OA, Al-Sawaf HA, Al-Bekairi AM. Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism. Biochem Mol Biol Int. 1999;47:153–9.PubMedGoogle Scholar
- Abdel-Wahab WM. Thymoquinone attenuates toxicity and oxidative stress induced by bisphenol a in liver of male rats. Pak J Biol Sci. 2014;17:1152–60.View ArticleGoogle Scholar
- Alenzi FQ, El-Bolkiny YS, Salem ML. Protective effects of Nigella sativa oil and thymoquinone against toxicity induced by the anticancer drug cyclophosphamide. Br J Biomed Sci. 2010;67:20–8.View ArticleGoogle Scholar
- Suddek GM. Protective role of thymoquinone against liver damage induced by tamoxifen in female rats. Can J Physiol Pharmacol. 2014;92:640–4.View ArticleGoogle Scholar
- Aras S, Gerin F, Aydin B, Ustunsoy S, Sener U, Turan BC, Armutcu F. Effects of sodium arsenite on the some laboratory signs and therapeutic role of thymoquinone in the rats. Eur Rev Med Pharmacol Sci. 2015;19:658–63.PubMedGoogle Scholar
- Abd-Elbaset M, Arafa EA, El Sherbiny GA, Abdel-Bakky MS, Elgendy AN. Thymoquinone mitigate ischemia-reperfusion-induced liver injury in rats: a pivotal role of nitric oxide signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2017;390:69–76.View ArticleGoogle Scholar
- Nagi MN, Almakki HA, Sayed-Ahmed MM, Al-Bekairi AM. Thymoquinone supplementation reverses acetaminophen-induced oxidative stress,nitricoxide production and energy decline in mice liver. Food Chem Toxicol. 2010;48:2361–5.View ArticleGoogle Scholar
- Hassanein KM, ElAmir YO. Protective effects of thymoquinone and avenanthramidesontitaniumdioxide nanoparticles induced toxicity in Sprague-Dawley rats. Pathol Res Pract. 2017;213:13–22.View ArticleGoogle Scholar